Targeting GSCs in combination with conventional therapies could be a promising therapeutic strategy for eradicating GBM, and several putative GSC surface markers, such as CD133, CD15, and CD44, and GSC transcription factors, such as SRY-box transcription factor 2 (SOX2), octamer-binding transcription factor 4 (OCT4), and NANOG, have been discovered [16]. This evidence concerns the gene POU5F1 and glioblastoma.